US 12,415,864 B2
Humanized antibodies against Lewis Y
Antje Danielczyk, Berlin (DE); Johanna Gellert, Berlin (DE); Anke Flechner, Berlin (DE); and Patrik Kehler, Berlin (DE)
Assigned to Pentixapharm AG, Würzburg (DE)
Appl. No. 18/010,858
Filed by Pentixapharm AG, Würzburg (DE)
PCT Filed Jun. 29, 2021, PCT No. PCT/EP2021/067767
§ 371(c)(1), (2) Date Dec. 16, 2022,
PCT Pub. No. WO2022/002887, PCT Pub. Date Jan. 6, 2022.
Claims priority of application No. 20183237 (EP), filed on Jun. 30, 2020.
Prior Publication US 2023/0235076 A1, Jul. 27, 2023
Int. Cl. C07K 16/28 (2006.01); A61K 47/68 (2017.01); A61P 35/00 (2006.01)
CPC C07K 16/2896 (2013.01) [A61K 47/6817 (2017.08); A61K 47/6849 (2017.08); A61P 35/00 (2018.01); C07K 2317/24 (2013.01); C07K 2317/33 (2013.01); C07K 2317/52 (2013.01); C07K 2317/565 (2013.01); C07K 2317/73 (2013.01); C07K 2317/92 (2013.01)] 18 Claims
OG exemplary drawing
 
1. A humanized antibody which is capable of binding to Lewis Y and which comprises a heavy chain variable region and a light chain variable region, wherein;
(a) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 10, and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 22;
(b) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 11 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 23;
(c) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 1 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(d) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 2 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(e) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 3 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(f) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 4 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(g) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 5 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(h) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 6 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(i) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 7 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 17;
(j) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 6 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 18; or
(k) the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 8 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 18.